Skip to main content

Tiziana Life Sciences Ltd

corporate_fare Company Profile

Tiziana Life Sciences Ltd

TLSA·NASDAQ·Life Sciences·CIK 0001723069

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company listed on NASDAQ under the ticker TLSA. The company specializes in developing therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets targeting Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic lateral sclerosis. Tiziana Life Sciences Ltd. was originally incorporated in England and Wales on February 11, 1998, and changed its name to Tiziana Life Sciences plc in April 2014 following the acquisition of Tiziana Pharma Limited. On October 20, 2021, the company completed a reorganization, establishing Tiziana Life Sciences Ltd., a Bermuda-incorporated company, as the ultimate parent company. Its registered office is in Hamilton, Bermuda.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for TLSA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Tiziana Life Sciences Announces $8.8M Public Offering at Deep Discount with Warrants
  • Tiziana Life Sciences Publishes Positive Foralumab Clinical Data in Peer-Reviewed Neurology Journal
  • Tiziana Life Sciences Closes $8.8M Offering Led by CEO and Chairman to Fund Clinical Trials
  • Tiziana Life Sciences Announces $6.5M Public Offering of Shares and Warrants at Significant Discount
  • Tiziana Life Sciences Secures $17.6M in Direct Offering Led by CEO and Chairman to Fund Clinical Trials

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$18.43M
Diluted EPS
-$0.16
Op. Cash Flow
-$12.85M
Free Cash Flow
-$12.87M
Operating Income
-$21.13M
Cash & Equivalents
$4.01M
Debt / Equity
0.00×
Shares Outstanding
2.1M sh
Source: 20-F · filed 2026-05-01 · accession 0001213900-26-051015

Insider Transactions

TLSA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.12
52-week range · as of 2026-09-30 $0.7615 – $2.33
Market cap
$143.71M
Volume
436.8K (0.7× avg)
3-mo avg 642K
Live data · 2026-10-05 05:56 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed TLSA - Filings & News (Page 2)

TLSA
Jan 21, 2026, 6:57 PM EST
Filing Type: 424B5
Importance Score:
8
Tiziana Life Sciences Announces $8.8M Public Offering at Deep Discount with Warrants
Price at Filing: $1.72
Real-time Price: $1.12 info
Change: -$0.600 (-35%) info
Market Cap: $143.706M info
Sentiment: Negative
View Wiseek Article
TLSA
Jan 20, 2026, 11:15 AM EST
Filing Type: 6-K
Importance Score:
7
Tiziana Life Sciences Publishes Positive Foralumab Clinical Data in Peer-Reviewed Neurology Journal
Price at Filing: $1.70
Real-time Price: $1.12 info
Change: -$0.575 (-34%) info
Market Cap: $143.706M info
Sentiment: Positive
View Wiseek Article
TLSA
Jan 16, 2026, 3:12 PM EST
Filing Type: 6-K
Importance Score:
7
Tiziana Life Sciences Closes $8.8M Offering Led by CEO and Chairman to Fund Clinical Trials
Price at Filing: $1.73
Real-time Price: $1.12 info
Change: -$0.605 (-35%) info
Market Cap: $143.706M info
Sentiment: Neutral
View Wiseek Article
TLSA
Jan 16, 2026, 7:39 AM EST
Filing Type: 424B5
Importance Score:
8
Tiziana Life Sciences Announces $6.5M Public Offering of Shares and Warrants at Significant Discount
Price at Filing: $1.68
Real-time Price: $1.12 info
Change: -$0.560 (-33%) info
Market Cap: $143.706M info
Sentiment: Negative
View Wiseek Article
TLSA
Jan 16, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
8
Tiziana Life Sciences Secures $17.6M in Direct Offering Led by CEO and Chairman to Fund Clinical Trials
Price at Filing: $1.69
Real-time Price: $1.12 info
Change: -$0.571 (-34%) info
Market Cap: $143.706M info
Sentiment: Neutral
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets